EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia

Mei Jiang iD, Xuemei Wang, Min Yu iD, Shuling Jiang, Miao Hong, Yuru Zhou, Fei Li, Hongxing Liu, Zhanglin Zhang

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27272 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Mei Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: the Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation, the major science and technology R & D projects of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IRF2BP1 breaked in the middle of exon 1 at the c.322 position and fused with RARA intron 2 which is located at 3717 bp upstream of its exon 3. The fusion produced a new intron by forming a paired splicing donor GT at 9 bp downstream of RARA breakpoint and acceptor AG at the 5' end of RARA exon 3. The IRF2BP1::RARA fusion gene leads a fusion transcript involving IRF2BP1 exon 1 and RARA exon 3, linked by a 9-bp fragment derived from RARA intron 2. The patient with IRF2BP1::RARA has same clinical features of APL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteHumansChromosomes, Human, Pair 17ExonsOncogene Proteins, FusionReceptors, Retinoic AcidRetinoic Acid Receptor alphaTranslocation, Genetic

Substanzen

Oncogene Proteins, FusionReceptors, Retinoic AcidRetinoic Acid Receptor alpha

Autor:innen und Institutionen

  • Department of Clinical Laboratory, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Blood Transfusion, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Hematology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Nursing School of Nanchang University, Nanchang, China.
  • Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Department of Blood Transfusion, Institute of transfusion, Jiangxi Key Laboratory of transfusion, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

ORCID-Profile: Mei Jiang, Min Yu

Förderung

  • the Natural Science Foundation of China
  • Jiangxi Provincial Natural Science Foundation
  • the major science and technology R & D projects of Jiangxi Province
  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Jiang, M., Wang, X., Yu, M., Jiang, S., Hong, M., Zhou, Y., Li, F., Liu, H., & Zhang, Z. (2024). Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27272

Vancouver

Jiang M, Wang X, Yu M, Jiang S, Hong M, Zhou Y, et al. Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27272

BibTeX
@article{Jiang2024,
  author = {Jiang, Mei and Wang, Xuemei and Yu, Min and Jiang, Shuling and Hong, Miao and Zhou, Yuru and Li, Fei and Liu, Hongxing and Zhang, Zhanglin},
  title = {Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27272}
}
Kostenlos starten →